您的位置: 专家智库 > >

国家自然科学基金(81070590)

作品数:4 被引量:12H指数:2
相关作者:付荣国刘晓丹葛蘅郭蕊军马峰更多>>
相关机构:西安交通大学医学院第二附属医院更多>>
发文基金:国家自然科学基金更多>>
相关领域:医药卫生更多>>

文献类型

  • 4篇中文期刊文章

领域

  • 4篇医药卫生

主题

  • 1篇凋亡
  • 1篇血液
  • 1篇血液透析
  • 1篇血液透析患者
  • 1篇肾切除
  • 1篇肾切除大鼠
  • 1篇肾透析
  • 1篇肾性
  • 1篇肾性贫血
  • 1篇肾脏
  • 1篇肾脏损伤
  • 1篇通络
  • 1篇通络方
  • 1篇透析患者
  • 1篇贫血
  • 1篇切除
  • 1篇人促红细胞生...
  • 1篇重组人促红细...
  • 1篇祛风
  • 1篇祛风通络

机构

  • 2篇西安交通大学...

作者

  • 2篇刘晓丹
  • 2篇付荣国
  • 1篇赵丽燕
  • 1篇王莉
  • 1篇马峰
  • 1篇郭蕊军
  • 1篇薛荣亮
  • 1篇袁浩峥
  • 1篇姚钢炼
  • 1篇李向利
  • 1篇葛蘅

传媒

  • 1篇陕西医学杂志
  • 1篇西安交通大学...
  • 1篇Journa...
  • 1篇Chines...

年份

  • 1篇2014
  • 1篇2013
  • 2篇2011
4 条 记 录,以下是 1-4
排序方式:
不同剂量rHuEPO对维持性血液透析患者肾性贫血的改善作用被引量:5
2011年
目的:观察大剂量重组人促红细胞生成素(rHuEPO)对维持性血液透析(MHD)患者肾性贫血的改善作用。方法:60例MHD患者随机分为3组:对照组(n=20):给予益比奥3000IU/次,静脉注射,3次/周。治疗1组(n=20):益比奥1万IU/周,1次静脉注射。治疗2组(n=20):益比奥1万IU/周,1次静脉注射,在血红蛋白上升至100g/L以后,改为3000IU/次,静脉注射,1次/周维持。总疗程6月。观察患者对透析的耐受以及血红蛋白(Hb)、红细胞压积(Hct)、血浆蛋白(TP)及血脂、肝、肾功能的改善情况。结果:治疗1组和2组在1个月时Hb、Hct即开始明显上升,1~3月上升幅度明显,4~6月上升减慢;同时患者精神状态明显好转;治疗结束时血浆总蛋白、白蛋白、转铁蛋白浓度均较前增加,肝功、肾功及血脂无显著性变化。但后期治疗1组患者血压有升高趋势。结论:大剂量rHuEPO应用可以快速纠正MHD肾性贫血,但血红蛋白上升至100g/L时建议改为3000 IU/周维持,减少医疗费用的同时可降低副反应。
刘晓丹付荣国王莉葛蘅马峰郭蕊军
关键词:肾透析
骨髓间充质干细胞对5/6肾切除大鼠肾脏损伤时Bcl-2、Bax表达的影响被引量:1
2011年
目的探讨骨髓间充质干细胞(BMSCs)移植对5/6肾切除大鼠肾损伤的保护作用,观察BMSCs对肾组织Bcl-2、Bax表达的影响。方法将雄性SD大鼠BMSCs用PKH26标记后注入受体雌性SD大鼠体内。40只受体雌性SD大鼠随机分为4组(n=10):假手术组、5/6肾切除+DMEM-F12组(模型组)、5/6肾切除+贝那普利组(对照组)、5/6肾切除+BMSCs组(干细胞组)。60d后观察肾功能改变;免疫组化法检测Bcl-2和Bax的表达,并观察PKH26标记的BMSCs在受体大鼠肾脏的分布情况。结果假手术组肾功能明显好于其余各组(P<0.05),对照组和干细胞组肾功能明显好于模型组(P<0.05);模型组Bcl-2、Bax表达及Bcl-2/Bax比值明显高于其余各组(P<0.05),干细胞组Bcl-2和Bax表达明显高于对照组(P<0.05)。5/6肾切除后第60d可见标记的BMSCs定位于肾组织中。结论外源性BMSCs可减少Bcl-2和Bax蛋白表达,下调Bcl-2/Bax比值,减少肾组织细胞凋亡,从而有利于肾功能的早期恢复。
袁浩峥姚钢炼付荣国刘晓丹张莉赵丽燕李向利薛荣亮
关键词:骨髓间充质干细胞细胞凋亡BCL-2BAX
Artemisinin ameliorated proteinuria in rats with adriamycin-induced nephropathy through regulating nephrin and podocin expressions被引量:5
2014年
OBJECTIVE:To investigate the effects of artemisinin against proteinuria and glomerular filtration barrier damage in rats with adriamycin-induced nephropathy,and the potential mechanism underpinned the action.METHODS:Forty adriamycin rats were randomly divided into two groups with the ratio of 1︰3;the small-number group served as control group(n=10),and the rats in the large-number group were treated with adriamycin to induce nephropathy;then they were further randomly assigned into 3subgroups:benazepril group(n=10),artemisiningroup(n=10),and adriamycin group(n=10).The benazepril group and artemisinin group were treated with benazepril suspl(5.0 mg/kg daily)and artemisinin suspl(150 mg/kg daily)respectively after being modeled;those in the control group and adriamycin group were intragastrically administered an equivalent volume of distilled water every day.The treatment after model establishment lasted for a total of 4 weeks.The 24 h uric protein,blood biochemicals,renal pathological changes,renal ultrastrutural changes,Nephrin and Podocin proteins and gene expressions were measured by Coomassie brilliant blue assay,completely automatic biochemical analyzer,light microscope,electron microscopy,Western blot and reverse transcription polymerase chain reaction,respectively.RESULTS:The rats in adriamycin group showed a significant increase in 24 h uric protein excretion,serum total cholesterol(TC),triglyceride(TG),blood urea nitrogen(BUN),serum creatinine(Scr)and decrease in albumin(Alb)(P<0.05 or P<0.01).Compared with adriamycin group,artemisinin could reduce uric protein excretion,decrease the serum TC,TG elevation,increase the serum Alb level,up-regulate the expressions of Nephrin and Podocin(P<0.05 or P<0.01),but no statistical significance effects on the levels of BUN,Scr in artemisinin group(P>0.05).The renal pathological and ultrastrutural observation indicate that artemisinin could attenuate the severity of foot process effacement and fusion in the nephropathic rats.CONCLUSION:Artemisinin might have an effe
Xili WuPeng AnBingyu YeXingmin ShiHuimin DangRongguo FuChenglin Qiao
关键词:ARTEMISININPROTEINURIANEPHRIN
Qufeng Tongluo Prescription(祛风通络方)Inhibits Mesangial Cell Proliferation and Promotes Apoptosis through Regulating Cell Cycle Progression被引量:1
2013年
Objective: To study the effects and possible underlying mechanism of Qufeng Tongluo Prescription (祛风通络方, QFTL) on the regulation of mesangial cells (MCs) proliferation and apoptosis. Methods: The MCs used in this experiment have undergone five passages induced by lipopolysaccharide (LPS). Changes in the proliferation, apoptosis, cell cycle regulatory proteins and mRNA expression levels of the MCs after administration of Benazepril or QFTL were measured by methyl thiazolyl tetrazolium (MTT) reduction assay, flow cytometry, Western blot and quantitative real-time polymerase chain reaction (qRT-PCR), respectively. Results: The addition of Benazepril or QFTL serum inhibited LPS-induced MC proliferation after treatment for 24, 48 and 72 h, respectively (P〈0.05 or P〈0.01). Moreover, the inhibitory effect is more significant in the QFTL group at 48 h (P〈0.05). Compared with the control group, LPS-induced cell proliferation decreased the number of cells in G1 phase versus cells in S and G2/M phases, while the addition of QFTL and Benazepril serum increased the ratio of cells at G1 phase (P〈0.05 or P〈0.01) to cells at S phase (P〈0.01), implicating the cell cycle inhibition effect exerted by QFTL. LPS decreased the level of MC apoptosis, compared with the control group (P〈0.05), while QFTL and Benazepril serum increased the level of MC apoptosis (P〈0.01). Moreover, the difference between the QFTL group and the Benazepril group was statistically significant (P〈0.01). Compared with the control group, the protein and mRNA expression levels of cylinD1, cyclin dependent kinase 2 (CDK2) and p21 were significantly increased (P〈0.05 or P〈0.01), p27 was decreased but with no statistical significance (P〉0.05); After being treated with QFTL and Benazepril serum, the protein and mRNA expression levels of cylinD1, CDK2, p21 were decreased and p27 increased significantly (P〈0.05 or P〈0.01); Compared with the Benazepril group, QFTL
吴喜利安鹏叶冰玉石兴民孙万森付荣国王竹乔成林
共1页<1>
聚类工具0